Vitality Watch

Dossier clinicaltrials trial early 01-oct-2026
Small or early-phase human trial or pilot study

Precision Microbiota Interventions for Senoreduction Trial

Key claim: A randomized, double-blind, crossover trial is evaluating two GRAS microbiota-targeted interventions on immune senescence biomarkers in people with HIV who drink alcohol.

Abstract

People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.

Why this matters

Microbiota-aimed ‘senoreduction’ is an emerging angle that borrows the senotherapeutics vocabulary without the senolytic drug risk profile, and this trial is one of the first to put it into a randomized clinical test in a population where immune aging is accelerated. Because the interventions are GRAS, the trend-to-evidence gap here is narrower than for peptide or biologic senolytics, but there is still no readout — the study is a probe, not a result.

Source

Link

Briefing card

Precision Microbiota Interventions for Senoreduction Trial
Stage: trial early · clinicaltrials · 01-oct-2026

Applies to participants enrolled in early microbiota-senoreduction trials — no outcome data yet to translate into a personal consequence.

A randomized, double-blind, crossover trial is evaluating two GRAS microbiota-targeted interventions on immune senescence biomarkers in people with HIV who drink alcohol.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07462767

build build 880 · 2bcef25 · 2026-11-18